Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials

医学 临床试验 癌症 泊松回归 内科学 肿瘤科 报销 毒性 人口 环境卫生 经济增长 医疗保健 经济
作者
Dai Chihara,Ruitao Lin,Christopher R. Flowers,Shanda Finnigan,Lisa M. Cordes,Yoko Fukuda,Erich P. Huang,Larry Rubinstein,Loretta J. Nastoupil,S. Percy Ivy,James H. Doroshow,Naoko Takebe
出处
期刊:The Lancet [Elsevier BV]
卷期号:400 (10351): 512-521 被引量:36
标识
DOI:10.1016/s0140-6736(22)01390-3
摘要

Summary

Background

The low expectation of clinical benefit from phase 1 cancer therapeutics trials might negatively affect patient and physician participation, study reimbursement, and slow the progress of oncology research. Advances in cancer drug development, meanwhile, might have favourably improved treatment responses; however, little comprehensive data exist describing the response and toxicity associated with phase 1 trials across solid tumours. The aim of the study is to evaluate the trend of toxicity and response in phase 1 trials for solid tumours over time.

Methods

We analysed patient-level data from the Cancer Therapy Evaluation Program of the National Cancer Institute-sponsored investigator-initiated phase 1 trials for solid tumours, from Jan 1, 2000, to May 31, 2019. We assessed risks of treatment-related death (grade 5 toxicity ratings possibly, probably, or definitely attributable to treatment), all on-treatment deaths (deaths during protocol treatment regardless of attribution), grade 3–4 toxicity, and proportion of overall response (complete response and partial response) and complete response rate in the study periods of 2000–05, 2006–12, and 2013–2019, and evaluated their trends over time. We also analysed cancer type-specific and investigational agent-specific response, and analysed the trend of response in each cancer type over time. Univariate associations of overall response rates with patients' baseline characteristics (age, sex, performance status, BMI, albumin concentration, and haemoglobin concentration), enrolment period, investigational agents, and trial design were assessed using risk ratio based on the modified Poisson regression model.

Findings

We analysed 465 protocols that enrolled 13 847 patients using 261 agents. 144 (31%) trials used a monotherapy and 321 (69%) used combination therapies. The overall treatment-related death rate was 0·7% (95% CI 0·5–0·8) across all periods. Risks of treatment-related deaths did not change over time (p=0·52). All on-treatment death risk during the study period was 8·0% (95% CI 7·6–8·5). The most common grade 3–4 adverse events were haematological; grade 3–4 neutropenia occurred in 2336 (16·9%) of 13 847 patients, lymphopenia in 1230 (8·9%), anaemia in 894 (6·5%), and thrombocytopenia in 979 (7·1%). The overall response rate for all trials during the study period was 12·2% (95% CI 11·5–12·8; 1133 of 9325 patients) and complete response rate was 2·7% (2·4–3·0; 249 of 9325). Overall response increased from 9·6% (95% CI 8·7–10·6) in 2000–05 to 18·0% (15·7–20·5) in 2013–19, and complete response rates from 2·5% (2·0–3·0) to 4·3% (3·2–5·7). Overall response rates for combination therapy were substantially higher than for monotherapy (15·8% [15·0–16·8] vs 3·5% [2·8–4·2]). The overall response by class of agents differed across diseases. Anti-angiogenesis agents were associated with higher overall response rate for bladder, colon, kidney and ovarian cancer. DNA repair inhibitors were associated with higher overall response rate in ovarian and pancreatic cancer. The rates of overall response over time differed markedly by disease; there were notable improvements in bladder, breast, and kidney cancer and melanoma, but no change in the low response of pancreatic and colon cancer.

Interpretation

During the past 20 years, the response rate in phase 1 trials nearly doubled without an increase in the treatment-related death rate. However, there is significant heterogeneity in overall response by various factors such as cancer type, investigational agent, and trial design. Therefore, informed decision making is crucial for patients before participating in phase 1 trials. This study provides updated encouraging outcomes of modern phase 1 trials in solid tumours.

Funding

National Cancer Institute.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zaizz发布了新的文献求助10
刚刚
自觉松完成签到,获得积分20
刚刚
刚刚
1秒前
ccy发布了新的文献求助20
1秒前
何松发布了新的文献求助10
1秒前
1秒前
华仔的应助被喔喔佳佳采纳,获得50
1秒前
dwfwq发布了新的文献求助10
1秒前
2秒前
蒸鱼完成签到 ,获得积分10
2秒前
撒德巴何猜想完成签到,获得积分10
2秒前
sunny的应助被Joff_W采纳,获得10
2秒前
3秒前
3秒前
leo关闭了leo的文献求助
3秒前
七七发布了新的文献求助30
3秒前
明理含之完成签到,获得积分10
3秒前
毛毛菇炒蛋完成签到,获得积分10
4秒前
我是老大的应助被诚心的以寒采纳,获得10
4秒前
4秒前
awadakendagua关注了科研通微信公众号
4秒前
yummy完成签到,获得积分10
4秒前
4秒前
科雨发布了新的文献求助10
5秒前
俏皮元珊发布了新的文献求助10
5秒前
别让zz读书完成签到,获得积分10
5秒前
5秒前
5秒前
6秒前
苏奇发布了新的文献求助30
6秒前
小面包发布了新的文献求助30
6秒前
大气手机完成签到,获得积分10
6秒前
虚幻白羊完成签到 ,获得积分10
7秒前
田様的应助被羊粑粑采纳,获得10
7秒前
香蕉觅云的应助被甜甜小兔子采纳,获得10
7秒前
华仔的应助被wu采纳,获得10
7秒前
外向的碧空完成签到,获得积分10
8秒前
8秒前
科目三的应助被冰_采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155737
求助须知:如何正确求助?哪些是违规求助? 9552018
关于积分的说明 21707687
捐赠科研通 7744923
什么是DOI,文献DOI怎么找? 3426177
关于科研通互助平台的介绍 2551229
邀请新用户注册赠送积分活动 2469949